Article
The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line.
DNA and cell biology - 1 Apr 2006
Nagatomo Izumi, Kumagai Toru, Yamadori Tadahiro, Furukawa Mitsugi, Takahashi Ryo, Yoneda Tsutomu, Ogata Yoshitaka, Saito Yoshiyuki, Inoue Koji, Yano Yukihiro, Kijima Takashi, Yoshida Mitsuhiro, Osaki Tadashi, Tachibana Isao, Greene Mark I, Kawase Ichiro
Abstract excerpt
A specific inhibitor of the Epidermal Growth Factor Receptor (EGFR), Gefitinib, displays significant antitumor effects against non-small cell lung cancers (NSCLC) that express EGFR with mutations in their tyrosine kinase domain. Although previous reports have already demonstrated that oncogenic t...
Topics
- Animals
- Antineoplastic Agents
- Cell Cycle
- Cell Line
- Cell Transformation, Neoplastic
- DNA
- Enzyme Activation
- ErbB Receptors
- Fibroblasts
- Gefitinib
- Mice
- Mitogen-Activated Protein Kinases
- Mutation